Pathogenetic features of acute naphazoline poisoning in children

Acute poisoning by nasal decongestants is an important issue in pediatrics due to physiological and anatomical characteristics of the child’s body and pharmacokinetics of drugs in early childhoo

ДИНАМИКА ЛИПОПОЛИСАХАРИДСВЯЗЫВАЮЩЕГО ПРОТЕИНА И ЛАКТАТА В КРОВИ ПАЦИЕНТОВ С ПОЛИТРАВМОЙ

Objective: to estimate the clinical and prognostic value of the blood levels of lipopolysaharidebinding protein (LPSBP) and lactate in critically ill polytrauma patients.Subjects and methods. An analysis was made of the results of an examination in critical ly ill polytrauma victims who were retrospectively classified in accordance with the 1992 ACCP/SCCM criteria: systemic inflammatory response syndrome (n=18), local infection (n=36), sepsis (n=27), severe sepsis (n=12), and septic shock (n=6). A case was regarded as infection when the source of the latter was established and it was microbiologically verified. The investigators determined serum LPSBP levels by an immunochemiluminescence analyzer (IMMULITE ONE, USA) and venous whole blood lactate concentrations by a Roche Omni S analyzer (Germany).Results. The development of infectious complications was notedin 81% of the polytrauma patients by days 5—7; by days 8—10, 45% were diagnosed as having sepsis whose severe course was characterized by the addition of polyresistant gramnegative microorganisms. An early increase in the concentration and frequency of diagnostic levels of serum LPSBP was ascertained in the polytrauma patients before infection was microbiologically verified. There was a strong direct correlation between lactate and LPSBP levels.Conclusion. The findings suggest that LPS BP and lactate are of diagnostic and prognostic value and may be used as early markers of pyoseptic complications.Цель исследования — оценить клиническую и прогностическую значимость уровней липополисахаридсвязывающего протеина (ЛПССП) и лактата в крови пациентов с политравмой в критическом состоянии.Материал и методы. Проведен анализ результатов обследования пострадавших с политравмой в критическом состоянии, которые ретроспективно были классифицированы в соответствии с критериями ACCP/SCCM (1992 г.): SIRS (n=18), локальная инфекция (n=36), сепсис (n=27), тяжелый сепсис (n=12) и септический шок (n=6). Случай считали инфекцией при установлении источника инфекции и его микробиологическом подтверждении. Содержание ЛПССП в сыворотке крови определяли на иммунохемилюминесцентном анализаторе «IMMULITE ONE» (США), лактата в цельной венозной крови — на анализаторе «Roche Omni S» (Германия).Результаты. У 81% пациентов с политравмой к 5—7 суткам отмечается развитие инфекционных осложнений; у 45% к 8—10 суткам диагностируется сепсис, тяжелое течение которого характеризуется присоединением полирезистентной грамотрицательной микрофлоры. Установлено раннее увеличение концентрации и частоты встречаемости диагностических уровней липополисахаридсвязывающего протеина (ЛПССП) в сыворотке крови у пациентов с политравмой до микробиологического подтверждения инфицирования. Показана сильная прямая корреляционная связь между уровнями лактата и ЛПССП.Заключение. Полученные данные свидетельствуют о диагностической и прогностической значимости ЛПССП и лактата и о возможности использования этих показателей в качестве ранних маркеров гнойносептических осложнений

Measurement of the cross-section and charge asymmetry of WW bosons produced in proton-proton collisions at s=8\sqrt{s}=8 TeV with the ATLAS detector

This paper presents measurements of the $W^+ \rightarrow \mu^+\nu$ and $W^- \rightarrow \mu^-\nu$ cross-sections and the associated charge asymmetry as a function of the absolute pseudorapidity of the decay muon. The data were collected in proton--proton collisions at a centre-of-mass energy of 8 TeV with the ATLAS experiment at the LHC and correspond to a total integrated luminosity of 20.2~\mbox{fb^{-1}}. The precision of the cross-section measurements varies between 0.8% to 1.5% as a function of the pseudorapidity, excluding the 1.9% uncertainty on the integrated luminosity. The charge asymmetry is measured with an uncertainty between 0.002 and 0.003. The results are compared with predictions based on next-to-next-to-leading-order calculations with various parton distribution functions and have the sensitivity to discriminate between them.Comment: 38 pages in total, author list starting page 22, 5 figures, 4 tables, submitted to EPJC. All figures including auxiliary figures are available at https://atlas.web.cern.ch/Atlas/GROUPS/PHYSICS/PAPERS/STDM-2017-13

Search for chargino-neutralino production with mass splittings near the electroweak scale in three-lepton final states in √s=13 TeV pp collisions with the ATLAS detector

A search for supersymmetry through the pair production of electroweakinos with mass splittings near the electroweak scale and decaying via on-shell W and Z bosons is presented for a three-lepton final state. The analyzed proton-proton collision data taken at a center-of-mass energy of √s=13  TeV were collected between 2015 and 2018 by the ATLAS experiment at the Large Hadron Collider, corresponding to an integrated luminosity of 139  fb−1. A search, emulating the recursive jigsaw reconstruction technique with easily reproducible laboratory-frame variables, is performed. The two excesses observed in the 2015–2016 data recursive jigsaw analysis in the low-mass three-lepton phase space are reproduced. Results with the full data set are in agreement with the Standard Model expectations. They are interpreted to set exclusion limits at the 95% confidence level on simplified models of chargino-neutralino pair production for masses up to 345 GeV

Search for direct stau production in events with two hadronic tau-leptons in root s=13 TeV pp collisions with the ATLAS detector

A search for the direct production of the supersymmetric partners ofτ-leptons (staus) in final stateswith two hadronically decayingτ-leptons is presented. The analysis uses a dataset of pp collisions corresponding to an integrated luminosity of139fb−1, recorded with the ATLAS detector at the LargeHadron Collider at a center-of-mass energy of 13 TeV. No significant deviation from the expected StandardModel background is observed. Limits are derived in scenarios of direct production of stau pairs with eachstau decaying into the stable lightest neutralino and oneτ-lepton in simplified models where the two staumass eigenstates are degenerate. Stau masses from 120 GeV to 390 GeV are excluded at 95% confidencelevel for a massless lightest neutralino

Search for new phenomena in final states with an energetic jet and large missing transverse momentum in pp collisions at √ s = 8 TeV with the ATLAS detector

Results of a search for new phenomena in final states with an energetic jet and large missing transverse momentum are reported. The search uses 20.3 fb−1 of √ s = 8 TeV data collected in 2012 with the ATLAS detector at the LHC. Events are required to have at least one jet with pT > 120 GeV and no leptons. Nine signal regions are considered with increasing missing transverse momentum requirements between Emiss T > 150 GeV and Emiss T > 700 GeV. Good agreement is observed between the number of events in data and Standard Model expectations. The results are translated into exclusion limits on models with either large extra spatial dimensions, pair production of weakly interacting dark matter candidates, or production of very light gravitinos in a gauge-mediated supersymmetric model. In addition, limits on the production of an invisibly decaying Higgs-like boson leading to similar topologies in the final state are presente

Psoriasis Regression Analysis of MHC Loci Identifies Shared Genetic Variants with Vitiligo

Psoriasis is a common inflammatory skin disease with genetic components of both immune system and the epidermis. PSOR1 locus (6q21) has been strongly associated with psoriasis; however, it is difficult to identify additional independent association due to strong linkage disequilibrium in the MHC region. We performed stepwise regression analyses of more than 3,000 SNPs in the MHC region genotyped using Human 610-Quad (Illumina) in 1,139 cases with psoriasis and 1,132 controls of Han Chinese population to search for additional independent association. With four regression models obtained, two SNPs rs9468925 in HLA-C/HLA-B and rs2858881 in HLA-DQA2 were repeatedly selected in all models, suggesting that multiple loci outside PSOR1 locus were associated with psoriasis. More importantly we find that rs9468925 in HLA-C/HLA-B is associated with both psoriasis and vitiligo, providing first important evidence that two major skin diseases share a common genetic locus in the MHC, and a basis for elucidating the molecular mechanism of skin disorders

Эффективность и безопасность применения бовгиалуронидазы азоксимера (Лонгидаза) у пациентов с постковидным синдромом: результаты открытого проспективного контролируемого сравнительного многоцентрового клинического исследования DISSOLVE

Post-COVID syndrome develops after COVID-19 (COronaVIrus Disease 2019) and leads to cumulative effects in the form of shortness of breath and impaired lung function. Notably, patients with airway inflammation and COVID-19 were found to have increased concentrations of hyaluronic acid (HA). Since bovhyaluronidase azoximer (Longidase®) catalyzes the hydrolysis of HA, this drug has the potential to reduce HA levels and improve lung function in patients with post-COVID syndrome.The aim of the DISSOLVE trial, which was conducted early in the pandemic, was to investigate the efficacy and safety of bovhyaluronidase azoximer in patients with symptoms associated with post-COVID syndrome.Methods. An open, prospective, controlled, comparative, multicenter clinical trial (NCT04645368) included adult patients (n = 160) who had post-COVID syndrome. Patients in the treatment group (n = 81) received bovhyaluronidase azoximer, and individuals in the control group (n = 79) were followed up without intervention. The study included physical examination, evaluation of forced vital capacity (FVC), assessment of dyspnea with the Modified Medical Research Council Dyspnea Scale (mMRC), 6-minute walking test, and pulse oximetry. These indicators were measured on 3 visits, at days 1 (baseline), 75, and 180. In addition, the number of patients who experienced adverse events and serious adverse events were recorded.Results. Baseline patient characteristics in the treatment group and the control group were similar. In the treatment group, there was a statistically significant reduction in residual pulmonary abnormalities after visit 2 (day 75) and visit 3 (day 180). In addition, FVC, pulse oximetry values, and functional exercise tolerance increased statistically significantly at days 75 and 180 compared to baseline. The mMRC scores for dyspnea decreased statistically significantly in the treatment group over 75 days. The safety profile of the drug was reported to be favorable throughout the study. Conclusion. Treatment with bovhyaluronidase azoximer in patients with post-COVID syndrome showed improvement in FVC, pulse oximetry, functional exercise tolerance, and mMRC dyspnea.Постковидный синдром (ПКС) после перенесенного COVID-19 (COronaVIrus Disease 2019) – это состояние, которое развивается у пациентов, переболевших COVID-19 и приводит к кумулятивным эффектам в виде одышки и нарушения функции легких. Примечательно, что у пациентов с воспалением дыхательных путей и COVID-19 обнаружены более высокие концентрации гиалуроновой кислоты (ГК). Поскольку бовгиалуронидаза азоксимер (Лонгидаза®) катализирует гидролиз ГК, при назначении данного препарата потенциально можно ожидать снижение концентрации ГК и улучшения функции легких у пациентов с ПКС.Целью исследования DISSOLVE, которое проводилось на начальной стадии пандемии, явилось изучение эффективности и безопасности применения бовгиалуронидазы азоксимера у пациентов с симптомами, связанными с ПКС.Материалы и методы. В открытом проспективном контролируемом сравнительном многоцентровом клиническом исследовании (NCT04645368) принимали участие взрослые пациенты (n = 160), у которых выявлен ПКС. Пациенты, составившие группу лечения (n = 81), получали бовгиалуронидазу азоксимер, лица, составившие группы контроля (n = 79), наблюдались динамически. В рамках исследования выполнялось физикальное обследование, проводилась оценка показателей форсированной жизненной емкости легких (ФЖЕЛ), одышки по шкале модифицированного вопросника Британского медицинского исследовательского совета (Modified Medical Research Council Dyspnea Scale – mMRC), дистанции, пройденной при выполнении 6-минутного шагового теста, и пульсоксиметрии. Эти показатели измерялись в рамках 3 визитов: в 1-й (исходный уровень), 75-й и 180-й дни. Кроме того, регистрировалось число пациентов, у которых наблюдались нежелательные явления (НЯ) и серьезные НЯ.Результаты. Исходные характеристики у пациентов группы лечения и контрольной группы были сходными. В группе лечения отмечено статистически значимое снижение остаточных легочных изменений после визита 2 (75-й день) и визита 3 (180-й день); кроме того, показатели ФЖЕЛ, пульсоксиметрии и переносимости функциональных физических нагрузок статистически значимо увеличились на 75-й и 180-й дни относительно исходного уровня. Показатели одышки по шкале mMRC в группе лечения статистически значимо снизились в течение 75 дней. Профиль безопасности препарата отмечался как благоприятный на протяжении всего исследования.Заключение. При терапии бовгиалуронидазой азоксимером у пациентов с ПКС отмечено улучшение показателей ФЖЕЛ, пульсоксиметрии, переносимости функциональных физических нагрузок и оценки одышки по mMRC